Pehea ka liʻiliʻi o nā CDMO Peptide ma waho o nā Pilikua e like me Lonza & Bachem

Pane wikiwiki

Compare specialized peptide CDMOs with mega-incumbents on customization speed, kālailai kūikawā, hikiwawe, and contract structuring strategies.

Pehea ka liʻiliʻi o nā CDMO Peptide ma waho o nā Pilikua e like me Lonza & Bachem

Ke hoʻololi nei ka ʻāina biopharma outsourcing. Ke alakaʻi ʻia nei e ka noi ʻoihana kūʻai mua ʻole no ka GLP-1 receptor agonists e like me semaglutide a me tirzepatide, Ua hana nā mega-CDMO e like me Lonza lāua ʻo Bachem i ka nui o ka reactor automated volume a me ka hiki ke hoʻomaʻemaʻe i nā ʻaelike hoʻolako pāʻoihana he mau haneli-kilogram.. E like me ka kikoʻī ma nā loiloi ʻoihana hou ma ka hoʻokaʻawale ʻana i ka mana hana peptide honua, Ua hoʻokumu kēia boom pāʻoihana i kahi bottleneck hana i manaʻo ʻole ʻia no nā ʻoihana biotechnology mua a hiki i waena.. ʻO nā mea hoʻomohala Biopharma e hoʻomohala ana i ka peptide therapeutics hou, peptide-lāʻau conjugates (Nā PDC), a paʻakikī i hoʻololi ʻia ke alo 9 i 18-mahina hoʻopaʻa laina laina, nā palena liʻiliʻi o ka hoʻolaha paʻa, a me nā alahele kamaʻilio ʻoihana ma Tier-1 CDMO.

Pehea ka liʻiliʻi o nā CDMO Peptide ma waho o nā Pilikua e like me Lonza & Bachem

Ma ka pane, kūikawā, ʻO nā CDMO agile peptide ka mea e ʻoi aku i nā mega-incumbent. Ma ka nānā ʻana i ka wikiwiki hoʻoponopono, hōʻike hoʻonaʻauao kūikawā, hiki i ke kaʻina hana synthetic, a me ke kākoʻo hoʻoponopono lima, Hāʻawi ka poʻe loea peptide liʻiliʻi i nā mea hana lapaʻau i nā pule ma mua o nā hapaha.

Hōʻike ka papa ma lalo nei i nā kālepa hana koʻikoʻi i ka wā e loiloi ana i kahi CDMO peptide kūikawā kūʻē i kahi mega-incumbent.:

Pehea ka liʻiliʻi o nā CDMO Peptide ma waho o nā Pilikua e like me Lonza & Bachem
Ana Hana Mega-CDMO Luna (Lonza, Bachem) Nā CDMO Peptide kūikawā
Ka Manawa Nui Hoʻolako GLP-1 pāʻoihana he mau haneli kilo ʻIke i ka pae hoʻokele (mg i ka nui-kg) nā hoʻolaha maʻamau
Ke Ana Hoʻohālike ʻepekema Nā Luna moʻokāki koʻikoʻi ʻole & nā tiketi koʻikoʻi ʻO ka hui pū ʻana me nā loea PhD synthesis kiʻekiʻe
Hoʻopilikino ʻoluʻolu Kemika paepae maʻamau & nā SOP paʻa Hoʻoponopono wikiwiki o 300+ hoʻololi pūʻulu hana
Hoʻonaʻauao Hoʻohālikelike Nā ʻano hana HPLC/MS ma waho o ka papa HPLC orthogonal i hoʻokaʻawale ʻia, LC-MS/MS, a me ka hoʻomohala ʻana i ke ʻano SEC
Kaiapuni hana Nā suites pāʻoihana nui ʻakomi Papa hikiwawe 100 nā lumi hoʻomaʻemaʻe ultra-sterile
Agility aelike Ka lōʻihi o ka hoʻopaʻa ʻana i nā pila & nā huaʻōlelo FFS paʻa Nā huaʻōlelo Hybrid FTE/FFS, hoʻomaka hoʻolaha wikiwiki, ʻōlelo IP agile

Pills 1: ʻO ka wikiwiki o ka hana a me ka hui pū ʻana o ka ʻepekema pololei

Ke hoʻopau nei i nā bottlenecks hoʻokele moʻokāki koʻikoʻi

Ke hui pū kekahi mea kākoʻo biopharma me kahi Tier-1 mega-CDMO, ke kamaʻilio maʻamau ma o ka ʻenehana Key Account Managers (KAM) a me nā keʻena hoʻokele papahana. Inā paʻa kahi paepae hoʻohui synthetic ma muli o ke kāohi steric a i ʻole hydrophobic aggregation, ʻO ka hoʻoponopono ʻana i ka pilikia e pono ai ka palapala kiʻi maʻamau, nā papa loiloi kūloko, a me ka hoʻopaneʻe ʻana i nā pule he nui.

Hoʻopau nā CDMO peptide kūikawā i kēia mau pale hoʻomalu. ʻO nā alakaʻi alakaʻi a me R&Hana pololei nā ʻepekema D me nā poʻokela synthesis chemists e hoʻokō nei i kā lākou hoʻolaha. Hiki i ke kamaʻilio ʻepekema-a-ʻepekema ke hoʻoholo i nā pilikia i ka manawa maoli, hoʻoponopono protocol wikiwiki, a me nā hōʻano hou holomua me ka ʻole o nā papa waena.

Pehea ka liʻiliʻi o nā CDMO Peptide ma waho o nā Pilikua e like me Lonza & Bachem

ʻOihana Kūlana Kūlana: Hoʻopiʻi Queue ma ka lako GMP Clinical

Hōʻike ka nānā ʻana i ka ʻoihana hou e koi pinepine ana nā mea hana CDMO tier-1 e hana ana ma 85-92% ka hoʻohana pono ʻana. 18-i-24-mahina alakai manawa no ka hoʻokaʻawale ʻana i ka reactor pāʻoihana a me ke pailaka. He ʻokoʻa, i ka wā e hoʻomohala ai nā mea kākoʻo biotech i hoʻololi ʻia i nā moho peptide i hoʻololi ʻia i nā CDMO peptide kūikawā me ka hoʻolālā lumi hoʻomaʻemaʻe agile, ʻO ka hoʻomaka ʻana o ka papahana i ka hāʻawi ʻana i nā tox non-GLP ua hoʻopili mau ʻia i 4–6 pule. Hoʻopau kēia hoʻokele ʻepekema pololei i nā lohi o nā mahina he nui a mālama i nā manawa hoʻouna koʻikoʻi IND ma ka papa kuhikuhi..

ʻO ka ʻimi ʻana i ke ala wikiwiki no nā kaʻina paʻakikī

ʻAʻole hahai ka chemistry peptide paʻakikī i hoʻokahi meaʻai maʻamau. Nā kaʻina i loaʻa nā ʻakika amino non-canonical, N-methylated koena, a i ʻole ka lōʻihi hydrophobic e ʻeha pinepine ʻia i nā hua hui haʻahaʻa a me ka hōʻuluʻulu beta-pepa i ka wā Solid-Phase Peptide Synthesis (SPSS).

Pehea ka liʻiliʻi o nā CDMO Peptide ma waho o nā Pilikua e like me Lonza & Bachem

ʻOiai ke hilinaʻi nei nā mega-CDMO i nā ʻōkuhi automated pre-validated, ʻoi aku ka maikaʻi o nā CDMO kūikawā ma ka mākaʻikaʻi ala wikiwiki. Hiki i kahi hui kūikawā ke nānā wikiwiki i nā mea hoʻohui hou (e like me HATU, PyBOP, a i ʻole phosphite-mediated hoʻohui), hoʻoponopono i ka nui o ka hoʻouka resin, a hoʻomaʻamaʻa maikaʻi i nā cocktails cleavage i loko o nā lā. E like me ka mea i hōʻike ʻia ma ke alakaʻi ma agile hoʻomohala peptide mua, ʻO kēia agility synthetic e hoʻopōkole i nā manawa alakaʻi no ke alakaʻi-optimization a me ka hana tox-batch.

Ki Takeaway: Hoʻopau ke kamaʻilio ʻepekema pololei me ka PhD synthesis chemists i nā papa palapala tiketi, e hōʻemi ana i nā kaʻina hoʻoponopono pilikia synthetic mua mai nā mahina a i nā lā.


Pills 2: ʻIkepili Kūikawā a me ka hoʻopaʻa inoa ʻino maʻamau

Ma waho aʻe o ka mana o ka maikaʻi

Hōʻike ʻia ka ʻano peptide i nā luʻina analytical kūʻokoʻa i hoʻohālikelike ʻia me nā molekele liʻiliʻi a i ʻole nā ​​​​antibody monoclonal. ʻOki ʻia nā kaʻina holoi holoi, nā diastereomers i loaʻa mai ka racemization i ka wā hoʻohui, a me nā huahana beta-aggregation pono i ka hoʻomohala hoʻolaʻa ʻana.

Ke hilinaʻi pinepine nei nā CDMO nui i ka standardized, kiʻekiʻe-throughput Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) nā ala i hoʻopaʻa ʻia no nā kaʻina maʻamau. Eia naʻe, peptides hoʻololi paʻakikī—e like me nā peptides stapled, nā hana pōʻaiapuni, a i ʻole nā ​​mea hana sulfide he nui—hoʻohui pinepine ʻia me nā haumia pili pili ma lalo o nā gradient maʻamau..

Hoʻokumu nā CDMO kūikawā i nā suite analytical maʻamau i kūpono i kēlā me kēia kaʻina kikoʻī. Hoʻomohala lākou i nā ʻano hana RP-HPLC orthogonal, kiʻekiʻe Electrospray Ionization Liquid Chromatography-Mass Spectrometry (ESI-LC-MS/MS) ʻāpana ʻāpana, a me ka Laki Ho'okae Chromatography (SEK) e nānā i nā mokuʻāina aggregation. Pili ana i ICH-compliant analytical characterization hōʻoia i kēlā ʻike, ka maemae, a ua hoʻokumu paʻa ʻia nā ʻaoʻao haumia ma mua o ka hoʻouna ʻana i ke kānāwai.

Hoʻohui ʻia ʻo Raw Synthetic → Orthogonal RP-HPLC Method → ​​High-Res ESI-LC-MS/MS → Counterion Swap → Palapala hōʻoia no ka nānā ʻana. (KoA)

Kūʻai Kūʻē a me ka Papa 100 Paʻa Pono

ʻO ka ʻakika trifluoroacetic maʻamau SPPS (TFA) ʻO ka wehe ʻana i nā koena TFA i hoʻopaʻa ʻia i nā koena peptide kumu. No nā hoʻokolohua kelepona, in vivo haʻawina holoholona, a i ʻole nā ​​papa hana lapaʻau, Hiki i ke koena TFA ke hoʻoulu i ka cytotoxicity a i ʻole hoʻololi i ka hana olaola. Hāʻawi nā CDMO kūikawā i nā kuʻina hoʻololi counterion i hoʻomalu ʻia, ka hoʻololi ʻana i nā paʻakai TFA i nā ʻano acetate a i ʻole hydrochloride i ka wā e hōʻoia ana i nā ratio counterion ma o ka ion chromatography.

Eia kekahi, Ke koi ikaika nei nā haʻawina hana biological i ka mālama ʻana i ka bioburden a me nā endotoxins. Nā lawelawe lawelawe kūikawā e hana ana ma kahi ultra-sterile Papa 100 kaiapuni lumi maʻemaʻe e hōʻoia i ka hoʻokō ʻana o nā pūʻulu maʻamau i nā kūlana sterility koʻikoʻi, ka pale ʻana i ka hoʻāʻo ʻana o ka cell-based a me preclinical mai nā mea hana kino.


Pills 3: Hoʻololi i ke kaʻina hana ma waena o SPPS, LPPS, a me nā hoʻololi paʻakikī

Nā Hana Hana Hana Hybrid

ʻOiai ʻo Solid-Phase Peptide Synthesis (SPSS) noho mau i ke kūlana gula no nā kaʻina pōkole a waena (a hiki i 30-40 koena), ʻO nā peptides lōʻihi a me nā pahuhopu pāʻoihana e pōmaikaʻi pinepine mai nā ala hybrid. ʻO ka wai-Phase Peptide Synthesis (LPPS) a i ʻole ʻāpana condensation (ka hoʻopili ʻana i nā ʻāpana peptide i pale pono ʻia i ka hopena) hiki ke hoʻokō i nā hua kiʻekiʻe aʻe a me nā ʻaoʻao maʻemaʻe maʻemaʻe no nā kaʻina paʻakikī.

Hoʻomaʻamaʻa pinepine ʻia nā Mega-CDMO a puni nā reactors SPPS automated, e hōʻole iā lākou e hoʻololi i nā hoʻonohonoho reactor no nā kaila hana SPPS/LPPS hybrid ma nā papahana haʻahaʻa haʻahaʻa.. Mālama nā CDMO kūikawā i nā hoʻonohonoho hana maʻalahi, hiki i ka hoʻololi ʻole ʻana ma waena o ka hui ʻāpana ʻāpana paʻa a me ka condensation ʻāpana wai..

Ka lawelawe ʻana 300+ Hoʻololi Pūʻulu Hana

Hoʻokomo nui nā moho lāʻau peptide hou i nā hoʻololi hoʻololi e hoʻonui i ka hapalua o ke ola plasma, kūpaʻa enzymatic, a me ke koho ʻana i ka pahuhopu. Aia kēia mau mea:

  • PEGylation kiko'ī pūnaewele a me ka hui ʻana o ka waikawa momona (e.g., nā kaulahao di-acid no ka hoʻopaʻa albumin)
  • Nā lepili fluorescent a me ka biotinylation no nā noi diagnostic a me nā kiʻi
  • Poʻo i ka huelo, kaulahao ʻaoʻao-a-ʻaoʻao, a me ka stapling hydrocarbon no ka conformational stabilization
  • Nā ʻenehana bioconjugation, me nā conjugates peptide-lāʻau (Nā PDC) a me nā pilina oligonucleotide-peptide

ʻO kahi CDMO kūikawā i hoʻolako ʻia e mālama i nā haneli o nā hoʻololi pūʻulu hana e hāʻawi i ka laulā ʻenehana i koi ʻia no nā kemika bioconjugation hou me ka ʻole o ka koi ʻana i nā mea kākoʻo e hoʻokele i nā sub-contractors..

No ke kōkua: I ka loiloi ʻana i kahi CDMO no nā peptides i hoʻololi ʻia, hōʻoia inā hoʻololi hana (e like me ka hōʻailona fluorescent a i ʻole stapling) hana ʻia i loko o ka hale a i waho paha. Hiki i ka hoʻololi ʻana i loko o ka hale ke mālama i ke kaulahao maʻemaʻe o ka mālama a pale i ka ʻike ʻana i ka waiwai naʻauao.


Pills 4: Hoʻolaʻa CMC a me ke kākoʻo hoʻoponopono

Agile Module 3 Nā waihona

Ke hoʻololi nei i kahi moho peptide mai ka noiʻi ʻana i ka Investigational New Drug (IND) a i ʻole ka palapala ʻenehana maʻamau (CTD) Module 3 Pono ka hoʻomākaukau ʻana i nā palapala kaʻina hana meticulous. Pono nā mea hoʻoponopono i ka ʻikepili kikoʻī e pili ana i nā kikoʻī mea hoʻomaka, nā ʻāpana synthesis, ʻano haumia, a me ka hō'oia 'analytical method.

Hāʻawi nā Mega-CDMO i nā pūʻolo hoʻoponopono maʻamau i hana ʻia e nā keʻena ʻoihana hoʻoponopono kikowaena. Hiki ke paakiki keia mau puolo, a me nā noi palapala maʻamau e loaʻa pinepine nā uku hoʻohui a me nā lohi hoʻonohonoho. Hāʻawi kokoke nā CDMO kūikawā, kākoʻo hoʻoponopono lima. Hoʻopili pololei kā lākou hui analytical a me ka maikaʻi me nā hui hoʻoponopono kākoʻo i ka Module i hoʻohālikelike ʻia 3 pauku, hāʻawi i nā kikoʻī analytical maka piha, a hoʻopilikino i nā moʻolelo pūʻulu no nā faila hoʻoponopono.

Hiki ke hoʻonui ʻia mai Milligrams a i Kilograms

ʻO kahi hopohopo maʻamau i waena o nā alakaʻi alakaʻi inā hiki i kahi CDMO loea ke kākoʻo i kahi moho ma mua o ka ʻike mua ʻana. Ke alakaʻi nei i nā mea hoʻolako peptide kūikawā e kamaʻilio i kēia ma ka hāʻawi ʻana i nā kahua hana scalable e hoʻomaka ana mai nā hale waihona puke screening milligram-scale a hiki i ka pilo multi-kilogram a me nā pūʻulu lapaʻau..

Ma ka mālama ʻana i ka hoʻomau o ke kemika ma ka ʻike, ʻaʻohe-GLP tox, a me ka hana mua o ke kino, pale nā ​​mea kākoʻo i ke kumukūʻai, pilikia laina manawa, a me ka hoʻopaʻapaʻa hoʻoponopono e pili ana i nā hoʻoili ʻenehana ma waena o nā ʻoihana.


Kūʻai Kūʻai Koho: ʻO ka manawa e makemake ai i kahi loea ma mua o kahi pilikua

E kōkua i nā alakaʻi kūʻai a me R&Hana nā luna D i nā hoʻoholo hoʻoholo i waho o ka ʻikepili, ʻO ka matrix ma lalo nei e wehewehe i nā mea hoʻoulu papahana nui a me nā koho CDMO i manaʻo ʻia:

Papahana Papahana / Hoʻomaka Manaʻo Hoa Kumu Hooholo Kumu
SAR preclinical & Hoʻonui alakaʻi (mg a i ka pālākiō g) CDMO kūikawā Pono ka hoʻololi synthetic wikiwiki, ka mākaʻikaʻi ala, a me ke kamaʻilio ʻepekema pololei.
Nā Hoʻololi Paʻakikī (Stapled, PDC, 300+ hoʻololi) CDMO kūikawā Koi i ka ʻike loea kemika a me ka hiki ke hoʻololi i loko o ka hale.
Puʻupuʻu Tox Track Fast (< 90-pono lā) CDMO kūikawā Kaʻalo ʻana i nā pila hoʻopaʻa slot lōʻihi ma nā mega-incumbent.
Hoʻolaha GLP-1 Kalepa (100+ kg koi makahiki) Mega-CDMO Hoʻohana nui i ka mana reactor multi-ton a me ka nui o ke kaulahao hoʻolako kalepa honua.
Māhele I/II Hoʻolako Kauka (1 kg i 10 pālākiō kg) CDMO kūikawā Hāʻawi i ka papa maʻalahi 100 hana lumi maʻemaʻe, kākoʻo CMC kūpono, a me ka maikaʻi o ke kumukūʻai.

Hoʻolālā Kūʻai Kūʻai: Ka Hopu ana i ka Pono Kuikaana

ʻO ka hui pū ʻana me kahi CDMO kūikawā e hāʻawi i ka ʻenehana a me ka hiki ke hana. Eia naʻe, ʻO ka hopu ʻana i kēia mau pōmaikaʻi e pono ai ke kūkulu ʻana i nā ʻaelike kūpono. Pono e hoʻokomo nā alakaʻi i nā hoʻolālā aelike ʻekolu:

1. Hybrid FTE vs. ʻŌlelo Kūʻai FFS

No nā papahana hoʻomaka mua kahi e ulu nei ke kemika sequence, Uku-No ka lawelawe paakiki (FFS) Hiki i nā ʻaelike ke alakaʻi i nā kauoha hoʻololi pinepine inā pono ka hoʻohui ʻana i nā ʻanuʻu i ka hoʻonui hou ʻana.

  • Kūlike manawa piha (FTE) Hoʻohālike: E hoʻohana i nā hoʻonohonoho FTE i ka wā o ka mākaʻikaʻi ala, Ka nānā ʻana i ka SAR, a me ke kaʻina hana. Hāʻawi kēia i ka mea kākoʻo i nā hola chemist i hoʻolaʻa ʻia a me ke kūʻokoʻa e pivot sequences me ka ʻole o ka ʻaelike hou ʻana.
  • Uku-No ka lawelawe (FFS) Hoʻohālike: E hoʻololi i nā huaʻōlelo FFS i hoʻopaʻa ʻia i ka milestone i ka wā i laka ʻia ai ke ala synthetic a neʻe ka hana ʻana i ka tox non-GLP a i ʻole nā ​​pūʻulu GMP clinical..

2. Nā SLA Hoʻololi aelike a me nā hoʻopaʻa ʻana i ka Līlani

ʻIke ʻia nā CDMO kūikawā no ka wikiwiki, akā, pono e hoʻokō nā ʻaelike i kēia mau manaʻo. E hōʻoia i ka ʻaelike e komo:

  • Nā SLA Hoʻokuʻu Analytical: ʻO nā puka makani hoʻokuʻu ʻia (e.g., 5-7 nā lā pāʻoihana ma hope o ka synthesis) no na Palapala Hoike (KoA), Hoʻopili maʻemaʻe HPLC, a me LC-MS spectra.
  • ʻO nā hōʻoiaʻiʻo o ka hana ʻana: Nā lā hoʻomaka ka hoʻomaka ʻana i kākoʻo ʻia e ka paukū e pili ana i ka hōʻea ʻana mai o nā mea waiwai, ka pale ʻana i ka neʻe ʻana o ka papahana i manaʻo ʻole ʻia.

3. Nā Pono Alahele Hoʻopaʻa IP a me Synthesis

Nā ala synthetic hou, nā papahana deprotection kūikawā, a me nā hana hoʻomaʻemaʻe maʻamau i kūkulu ʻia i ka wā hoʻolaha e hōʻike ana i ka waiwai kūʻai nui. Pono nā ʻaelike e kuhikuhi pono i kēlā:

  • ʻO nā waiwai noʻonoʻo synthetic synthetic a pau, nā hana hoʻomaikaʻi, a me nā ʻano analytical i hana ʻia i ka wā o ka papahana 100% na ka mea kokua.
  • Nā pūʻolo hoʻoili ʻenehana piha, me nā moʻolelo pūʻulu maka piha a me nā palapala hana haku, hiki ke loaʻa ma ke noi.

Ke koho ʻana i ka hoa kūpono no kāu Pipeline Peptide

ʻO ka hoʻoholo ma waena o kahi Tier-1 mega-CDMO a me kahi loea agile ʻaʻole ia e pili ana i ka loaʻa ʻana o kahi mea kūʻai aku "maikaʻi" hoʻokahi., akā, e hoʻohālikelike i ka ikaika o ka mea kūʻai aku me ke kūlana o ka papahana. ʻOiai ʻo nā mega-incumbents e like me Lonza a me Bachem e noho koʻikoʻi no nā blockbusters pāʻoihana kiʻekiʻe, Hāʻawi nā CDMO kūikawā i ka wikiwiki, hui ʻepekema, a me ka maʻalahi synthetic no ka ʻike ʻana ma o nā moho peptide pae lapaʻau.

Nā kākoʻo e ʻimi nei i ka hoʻokō hoʻolaha wikiwiki, nā hoʻololi hana kiʻekiʻe, a hiki i ka launa pū ʻana ke hana pū me a kahua kūikawā peptide synthesis like MOL Changes. Me ka ʻike nui ma SPPS, LPPS, a me kemika bioconjugation, he waihona hoonui o 300+ hoʻololi pūʻulu hana, a Papa 100 nā lumi hoʻomaʻemaʻe ultra-sterile, Kōkua ʻo MOL Changes i nā mea hoʻomohala biopharma e hoʻolalelale i nā moho peptide paʻakikī mai ke kahua a i ke keʻena hauʻoli.


No ka mea kakau

Ua ʻōlelo ʻo Dr. Elena Rostova lawelawe ʻo ia ma ke ʻano he Hope Peresidena o ka Hoʻomohala Kaʻina Peptide & CMC. Me ka oi 15 makahiki o ka ʻike i ka solid-phase peptide synthesis (SPSS), wai-phase fragment condensation, a me kemika bioconjugation, Ua ʻōlelo ʻo Dr. Ua alakaʻi ʻo Rostova i ka hoʻomohala ʻana i ke kaʻina hana a me ka hōʻike analytical no nā kaukani o nā moho lāʻau lapaʻau peptide-pae.. Kākoʻo kāna hana i ka hoʻokē ʻai ʻana i nā kaʻina hana paʻakikī, nā kuʻina hoʻololi kūʻē, a me ka Module hooponopono 3 nā hoʻouna no nā mea hou biopharma e kū nei.

Zejun Peng

Zejun Peng

Luna ʻenehana Nui; ʻO ka mea akamai i ka peptide Synthesis Kaʻike kumu: ʻO ka peptide synthesis paʻakikī, nā hoʻololi ʻana o ka amino acid kūlohelohe, a me ke kūkulu ʻana i nā peptides cyclic a me nā peptides stapled.

moʻokalaleo:He ʻike nui ʻo Zejun Peng i ka kemika kūlohelohe a me ka synthesis peptide. Maikaʻi ʻo ia i ka hoʻohana ʻana o ka solid-phase peptide synthesis (SPSS) a me ka peptide synthesis wai (LPPS), a akamai loa i ka lanakila ʻana i nā "paʻakikī loa-e-synthesize sequences" (e like me nā peptides ultra-long-chain, nā kaʻina hydrophobic kiʻekiʻe, a me ka pelu ana i na mea paa disulfide lehulehu). Ma lalo o kāna alakaʻi, ua lanakila ka hui i nā bottlenecks ʻenehana i kekahi mau hoʻololi kūikawā (e like me ka N-methylation, PEGylation, a me ka lepili fluorescent), ka mālama ʻana i ka helu kūleʻa synthesis o luna 98%.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana